Tamir Meiri will cover how Johnson & Johnson Venture Investments invests and supports globally to bring strategic value to companies […]
Jared Sorin, co-leader of the Emerging Companies and Venture Capital practice group & Adam Schoen, Partner at Brown Rudnick, will […]
Healthcare organizations from all corners are competing to leverage flexible technology infrastructure to rapidly push out offerings that meet consumer […]
Obtaining a CPT code, either a new code or the use of an existing code, is essential for many new […]
Speaker: Ian Duncan, Santa Barbara Actuaries
Tuesday, November 16, 1:00 to 2:00 PM PT
You have developed a great new device, founded a winning healthcare startup, obtained FDA certification… but have you thought about how you will be paid for the startup/device/intervention? Don’t ignore reimbursement until it’s too late. Now is the time to start honing your economic value proposition to payers. Join us to hear from Ian Duncan of Santa Barbara Actuaries. Ian will tell us about all the key points that healthcare companies need to take into consideration when planning their reimbursement and payer strategies.
Topics to be covered:
- Does your solution address a condition or aspect of healthcare that is sufficiently costly for a payer/employer to devote its limited time and resources to? (Yes, there are some rule-of-thumb thresholds).
- What do payers care about? (answer: PMPM; but can your solution be administered?).
- What is ROI and do you need ROI evidence to support your economic case?
- How much evidence is enough evidence? Do you need peer-reviewed outcomes (probably not, though it’s nice to have).
- Calculating ROI: With and without sufficient real-world data.
- What about other aspects of the value equation (absenteeism/productivity)?
- What is the fastest and easiest way to get the evidence needed to sell?
- An interactive economic model can be a great sales tool. (All payers think their population is different to all the others).
- Have you thought about who needs your intervention from an ROI/value creation standpoint?
- Have you thought about how to optimize, not maximize, your program’s engagement?
Speaker: Lifei Cheng, Founder & CEO, MedTecX
Thursday, June 3, 3:00 to 4:00 PM PST
China’s growing economy is something that we can no longer ignore. With the largest population in the world, China is or will soon be the largest healthcare market. For decades, China has been of strategic interest to many large US medtech companies. Yet entering its market seems intimidating, especially to startups. The Chinese government wants to expand its healthcare reach and bring high-quality care to its billions of citizens. The Chinese medtech sector is looking for cross-border collaborations to jump-start innovation to serve their needs. Join this webinar to learn what it takes to bring your technology to China, what potential pitfalls to watch for, what’s real and what’s a myth about doing business in China.
Speakers: Shefali Shah & Louis Jacques, ADVI
Thursday, May 27, 1:00 to 2:00 PM PST
Ever-increasing costs have kept the topic of healthcare coverage, reimbursement, and pricing in the spotlight. While innovators must be sensitive to the short-term goals of their investors, those “quick wins” in the development or regulatory phases may stymie the efficient attainment of long-term goals for favorable coverage and payment by public and commercial health insurers. Value has become a buzzword, but what does it mean? And what does it mean to different audiences? While some feel the assessment of value is opaque and challenging, health insurers (buyers) believe that the message is clear enough but largely ignored because it doesn’t match what developers (sellers) want to hear.
Speakers: Michael Cohen, Brown Rudnick
Tuesday, February 9, 1:00 to 2:00 PM PST
Most emerging companies with rapid growth plans will seek venture financing. Whether you sell SAFE, convertible notes, or preferred stock, venture investors expect that your financing will feature standard rights and use accepted documentation, but that isn’t the end of the story. Decisions about valuation, founders’ rights, and control over decision making can have long-lasting impacts on the company, and the interests of the investors will quickly deviate from those of the original stockholders. It is important to understand the financing process, where there is room to negotiate, and which investor rights are non-negotiable. This talk will walk through the process of a typical venture investment, starting at the term sheet stage and moving through the definitive documents. We will focus on real-life examples and the consequences of certain decisions in the lead-up to closing.
Speakers: Rachel Zeldin, Health & Life Sciences practice group at Oliver Wyman
Wednesday, January 20, 1:00 to 2:00 PM PST
Employers are a critical stakeholder in the US healthcare system: 49% of Americans receive health coverage through their employer, and employers spend $1.2T on healthcare today. Given this, the employer market is a natural starting point for emerging healthcare companies. But what do employers want, and how is this changing? How should emerging healthcare companies position themselves to address employer concerns? How should healthcare companies selling directly to employers think about other market stakeholders – brokers, health plans, PBMs, providers? During this talk, we will address all three of these questions, and share lessons learned from healthcare technology companies that have built successful businesses in the employer-sponsored market.
Speakers: Adam Schoen & Sam Williams, Partners, Brown Rudnick
Tuesday, December 8, 1:00 to 2:00 PM PST
Agreements are the lifeblood of any emerging company. License agreements typically allow founders to bring their technology out of the academic setting and into their companies. Master service agreements are a very common avenue by which emerging companies work with vendors to accomplish research objectives. Collaboration agreements typically define relationships between a company and an industry partner or larger strategic. Understanding these agreements and avoiding pitfalls are critical. This talk with explain the different aspects of such agreements and how they are viewed by venture investors and other strategic partners.